newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory Meeting

– Company is aligned with the FDA on next steps for a 351(k) regulatory pathway to approval for ABP-450 (prabotulinumtoxinA) as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product – –